Vistagen Therapeutics, Inc. (VTGN)

3,3200 +0,0900 (+2,79 %) À la clôture : 04:00PM EDT

Vistagen Therapeutics, Inc.

343 Allerton Avenue
South San Francisco, CA 94080
United States
650 577 3600
https://www.vistagen.com

Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 39

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Mr. Shawn K. Singh J.D.	CEO & Director	947,92k	S.O.	1963
Ms. Cynthia Lynn Anderson CPA	Chief Financial Officer	391,2k	S.O.	1969
Mr. Joshua S. Prince M.B.A.	Chief Operating Officer	568,44k	S.O.	1971
Mr. Reid G. Adler Esq., J.D.	Chief Corporate Development Officer & General Counsel	675k	S.O.	1955
Mr. Mark Adrian McPartland	Senior Vice President of Investor Relations	300k	S.O.	1966
Ms. Trisha Fitzmaurice	Senior Vice President of Human Resources	S.O.	S.O.	S.O.
Dr. Allen Easley Cato III, M.D., Ph.D.	Senior Vice President of Development Operations	S.O.	S.O.	S.O.
Dr. Mark J. Ginski Ph.D.	Senior VP and Head of Chemistry, Manufacturing & Controls	S.O.	S.O.	1972
Mr. Mark Flather	Senior Vice President of Corporate Strategy & Capital Markets	S.O.	S.O.	S.O.
Dr. Erik Berglund M.D., Ph.D.	Senior VP of Global Regulatory Affairs & Pharmacovigilance	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2024 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Vistagen Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for psychiatric and neurological disorders. The company's product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. It also develops PH80, a hormone-free, odorless, and tasteless synthetic investigational neuroactive pherine nasal spray for the treatment of menopausal hot flashes related vasomotor symptoms and other women's health indications; PH15, an investigational neuroactive to treat improve psychomotor or cognitive impairment caused by mental fatigue; PH284, an early-stage investigational neuroactive steroid for the treatment of investigational neuroactive pherine nasal spray for the treatments of loss of appetite associated with chronic disorders, such as cancer or heart disease, as well as cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain to treat disorders. In addition, the company's clinical-stage pipeline consists of intranasal product candidates from a new class of potential neuroscience therapies comprising pherines. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Vistagen Therapeutics, Inc. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.